{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:55:44Z","timestamp":1777593344971,"version":"3.51.4"},"reference-count":99,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,11]],"date-time":"2024-12-11T00:00:00Z","timestamp":1733875200000},"content-version":"am","delay-in-days":376,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIDDK123381"],"award-info":[{"award-number":["NIDDK123381"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.clinthera.2023.10.013","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T21:37:30Z","timestamp":1700257050000},"page":"1171-1176","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Past, Present, and Future Therapies for Alcohol-associated Hepatitis"],"prefix":"10.1016","volume":"45","author":[{"given":"Sally","family":"Condon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9364-5796","authenticated-orcid":false,"given":"Loretta L.","family":"Jophlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2023.10.013_bib0001","first-page":"69","article-title":"Cirrhosis of the liver: five different types of lesions from which it may arise","volume":"22","author":"Mallory","year":"1911","journal-title":"Bull Johns Hopkins Hosp"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0002","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/bmj.1.4029.661","article-title":"The Physical Basis of \"Biliousness.\"","volume":"1","author":"Hurst","year":"1938","journal-title":"Br Med J"},{"issue":"Suppl 5","key":"10.1016\/j.clinthera.2023.10.013_bib0003","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/s12918-017-0464-7","article-title":"A systematic analysis of FDA-approved anticancer drugs","volume":"11","author":"Sun","year":"2017","journal-title":"BMC Syst Biol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0004","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1056\/NEJMoa1412278","article-title":"Prednisolone or pentoxifylline for alcoholic hepatitis","volume":"372","author":"Thursz","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0005","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","article-title":"Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo\u2014a meta-analysis of individual data from controlled trials","volume":"155","author":"Louvet","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0006","first-page":"973","article-title":"Women's health and clinical trials","volume":"112","author":"Schiebinger","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0007","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.jhep.2022.04.026","article-title":"The stigma of alcohol-related liver disease and its impact on healthcare","volume":"77","author":"Schomerus","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0008","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s10620-013-2942-0","article-title":"Consequences of perceived stigma among patients with cirrhosis","volume":"59","author":"Vaughn-Sandler","year":"2014","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0009","unstructured":"Available from: https:\/\/nida.nih.gov\/research-topics\/addiction-science\/words-matter-preferred-language-talking-about-addiction."},{"key":"10.1016\/j.clinthera.2023.10.013_bib0010","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","article-title":"Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA Alcoholic Hepatitis Consortia","volume":"150","author":"Crabb","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0011","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1111\/acer.13515","article-title":"Challenges in patient enrollment and retention in clinical studies for alcoholic hepatitis: experience of the TREAT Consortium","volume":"41","author":"Comerford","year":"2017","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0012","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0002-9343(84)90776-9","article-title":"Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis","volume":"76","author":"Mendenhall","year":"1984","journal-title":"Am J Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0013","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1177\/0148607185009005590","article-title":"VA Cooperative Study on Alcoholic Hepatitis. III: changes in protein-calorie malnutrition associated with 30 days of hospitalization with and without enteral nutritional therapy","volume":"9","author":"Mendenhall","year":"1985","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0015","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.cgh.2016.08.047","article-title":"Medical management of severe alcoholic hepatitis: Expert Review from the Clinical Practice Updates Committee of the AGA Institute","volume":"15","author":"Mitchell","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0016","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","article-title":"ACG Clinical Guideline: Alcoholic Liver Disease","volume":"113","author":"Singal","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0017","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.jhep.2018.03.018","article-title":"EASL Clinical Practice Guidelines: Management of alcohol-related liver disease","volume":"69","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0018","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","article-title":"Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the American Association for the Study of Liver Diseases","volume":"71","author":"Crabb","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0019","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.clnu.2018.12.022","article-title":"ESPEN guideline on clinical nutrition in liver disease","volume":"38","author":"Plauth","year":"2019","journal-title":"Clin Nutr"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0020","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1053\/jhep.2000.8627","article-title":"Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: a multicenter randomized trial","volume":"32","author":"Cabre","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0021","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1053\/j.gastro.2015.12.038","article-title":"Intensive enteral nutrition is ineffective for patients with severe alcoholic hepatitis treated with corticosteroids","volume":"150","author":"Moreno","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0022","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.jhep.2007.10.010","article-title":"Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids","volume":"48","author":"Louvet","year":"2008","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0023","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1023\/A:1018838808396","article-title":"Early feeding or enteral nutrition in patients with cirrhosis after bleeding from esophageal varices? A randomized controlled study","volume":"42","author":"de Ledinghen","year":"1997","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0024","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.12968\/bjon.2020.29.20.1148","article-title":"Equal efficacy of gastric and jejunal tube feeding in liver cirrhosis and\/or alcoholic hepatitis: a randomised controlled study","volume":"29","author":"Bager","year":"2020","journal-title":"Br J Nursing"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0025","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0168-8278(88)80483-5","article-title":"A randomized controlled study of peripheral parenteral nutrition in moderate and severe alcoholic hepatitis","volume":"7","author":"Simon","year":"1988","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0026","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1016\/j.jhep.2021.06.019","article-title":"Identification of optimal therapeutic window for steroid use in severe alcohol-associated hepatitis: a worldwide study","volume":"75","author":"Arab","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0027","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/ajg.2016.539","article-title":"A day-4 Lille Model predicts response to corticosteroids and mortality in severe alcoholic hepatitis","volume":"112","author":"Garcia-Saenz-de-Sicilia","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0028","doi-asserted-by":"crossref","first-page":"854","DOI":"10.7326\/0003-4819-33-4-854","article-title":"Adrenal cortex in liver disease","volume":"33","author":"Webster","year":"1950","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0029","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1136\/bmj.2.5260.1113","article-title":"Acute alcoholic hepatitis","volume":"2","author":"Beckett","year":"1961","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0030","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197106172842404","article-title":"Corticosteroid therapy in severe alcoholic hepatitis. A double-blind drug trial","volume":"284","author":"Porter","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0031","first-page":"52","article-title":"[Glucocorticosteroids for people with alcoholic hepatitis (Cochrane review)]","volume":"91","author":"Pavlov","year":"2019","journal-title":"Ter Arkh"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0032","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gut.2010.224097","article-title":"Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data","volume":"60","author":"Mathurin","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0033","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/0016-5085(78)90401-8","article-title":"Corticosteroid therapy of alcoholic hepatitis","volume":"75","author":"Maddrey","year":"1978","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0034","doi-asserted-by":"crossref","first-page":"e913","DOI":"10.1016\/j.cgh.2021.04.017","article-title":"Trajectory of serum bilirubin predicts spontaneous recovery in patients with alcoholic hepatitis","volume":"20","author":"Weng","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0035","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.14309\/ajg.0000000000000912","article-title":"In severe alcoholic hepatitis, serum keratin-18 fragments are diagnostic, prognostic, and theragnostic biomarkers","volume":"115","author":"Atkinson","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0036","article-title":"Differential blood transcriptome modules predict response to corticosteroid therapy in alcoholic hepatitis","volume":"3","author":"Sharma","year":"2021","journal-title":"JHEP Rep"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0037","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3350\/cmh.2020.0196","article-title":"Predictors of steroid non-response and new approaches in severe alcoholic hepatitis","volume":"26","author":"Sarin","year":"2020","journal-title":"Clin Mol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0038","doi-asserted-by":"crossref","first-page":"j1415","DOI":"10.1136\/bmj.j1415","article-title":"Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study","volume":"357","author":"Waljee","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0039","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.clinre.2017.06.001","article-title":"Circulating levels of bacterial DNA and risk of infections in severe alcoholic hepatitis","volume":"41","author":"Louvet","year":"2017","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0040","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.hep.2003.09.038","article-title":"Early change in bilirubin levels is an important prognostic factor in severe alcoholic hepatitis treated with prednisolone","volume":"38","author":"Mathurin","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0041","doi-asserted-by":"crossref","first-page":"27","DOI":"10.3390\/jcm10112338","article-title":"Day-4 Lille score is a good prognostic factor and early predictor in assessing therapy response in patients with liver cirrhosis and severe alcoholic hepatitis","volume":"10","author":"Foncea","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0042","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1136\/gut.13.9.690","article-title":"Corticosteroids in liver disease: studies on the biological conversion of prednisone to prednisolone and plasma protein binding","volume":"13","author":"Powell","year":"1972","journal-title":"Gut"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0043","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/j.1365-2125.1978.tb01664.x","article-title":"Prednisone or prednisolone for the treatment of chronic active hepatitis? A comparison of plasma availability","volume":"5","author":"Davis","year":"1978","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0044","first-page":"27","article-title":"IL-1 receptor antagonist plus pentoxifylline and zinc for severe alcohol-associated hepatitis","volume":"27","author":"Szabo","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0045","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1152\/ajplegacy.1975.229.5.1344","article-title":"Effects of glucagon and insulin on net hepatic metabolism of glucose precursors in sheep","volume":"229","author":"Brockman","year":"1975","journal-title":"Am J Physiol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0046","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/0016-5085(81)90250-X","article-title":"A randomized clinical trial of insulin and glucagon infusion for treatment of alcoholic hepatitis: progress report in 50 patients","volume":"80","author":"Baker","year":"1981","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0047","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/S0168-8278(87)80577-9","article-title":"A prospective multicenter study of insulin and glucagon infusion therapy in acute alcoholic hepatitis","volume":"5","author":"Feher","year":"1987","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0048","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1002\/hep.1840140625","article-title":"Insulin and glucagon infusion in acute alcoholic hepatitis: a prospective randomized controlled trial","volume":"14","author":"Bird","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0049","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1002\/hep.1840150115","article-title":"Treatment of severe alcoholic hepatitis by infusion of insulin and glucagon: a multicenter sequential trial","volume":"15","author":"Trinchet","year":"1992","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0050","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0016-5085(79)80136-5","article-title":"Effect of short-term therapy with propylthiouracil in patients with alcoholic liver disease","volume":"76","author":"Orrego","year":"1979","journal-title":"Gastroenterology"},{"issue":"5 Pt 1","key":"10.1016\/j.clinthera.2023.10.013_bib0051","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S0016-5085(82)80257-6","article-title":"Double-blind, controlled trial of propylthiouracil in patients with severe acute alcoholic hepatitis","volume":"82","author":"Halle","year":"1982","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0052","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1056\/NEJM198412063112302","article-title":"Short-term and long-term survival in patients with alcoholic hepatitis treated with oxandrolone and prednisolone","volume":"311","author":"Mendenhall","year":"1984","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0053","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.1840170407","article-title":"A study of oral nutritional support with oxandrolone in malnourished patients with alcoholic hepatitis: results of a Department of Veterans Affairs cooperative study","volume":"17","author":"Mendenhall","year":"1993","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0054","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0168-8278(03)00476-8","article-title":"A randomized placebo controlled trial of vitamin E for alcoholic hepatitis","volume":"40","author":"Mezey","year":"2004","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0055","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2005.11.039","article-title":"Antioxidants versus corticosteroids in the treatment of severe alcoholic hepatitis\u2014a randomised clinical trial","volume":"44","author":"Phillips","year":"2006","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0056","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jhep.2007.03.027","article-title":"A randomized trial of antioxidant therapy alone or with corticosteroids in acute alcoholic hepatitis","volume":"47","author":"Stewart","year":"2007","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0057","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1016\/S0016-5085(99)70354-9","article-title":"Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice","volume":"117","author":"Yin","year":"1999","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0058","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0168-8278(02)00230-1","article-title":"Combination of steroids with infliximab or placebo in severe alcoholic hepatitis: a randomized controlled pilot study","volume":"37","author":"Spahr","year":"2002","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0059","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/hep.20206","article-title":"A double-blind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0060","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.jhep.2008.10.024","article-title":"Infliximab monotherapy for severe alcoholic hepatitis and predictors of survival: an open label trial","volume":"50","author":"Sharma","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0061","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1572-0241.2004.04034.x","article-title":"A pilot study of the safety and tolerability of etanercept in patients with alcoholic hepatitis","volume":"99","author":"Menon","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0062","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0063","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1002\/hep.30761","article-title":"Phosphodiesterase 4 inhibition as a therapeutic target for alcoholic liver disease: from bedside to bench","volume":"70","author":"Rodriguez","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0064","first-page":"96A","article-title":"Pentoxifylline may prevent renal impairment (hepatorenal-syndrome) in severe acute alcoholic hepatitis","volume":"14","author":"McHutchison","year":"1991","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0065","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1053\/gast.2000.20189","article-title":"Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial","volume":"119","author":"Akriviadis","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0066","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1007\/s10620-012-2097-4","article-title":"Corticosteroid plus pentoxifylline is not better than corticosteroid alone for improving survival in severe alcoholic hepatitis (COPE trial)","volume":"57","author":"Sidhu","year":"2012","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0067","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2013.276300","article-title":"Prednisolone with vs without pentoxifylline and survival of patients with severe alcoholic hepatitis: a randomized clinical trial","volume":"310","author":"Mathurin","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0068","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD007339.pub2","article-title":"Pentoxifylline for alcoholic hepatitis","author":"Whitfield","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0069","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/apt.12279","article-title":"Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis","volume":"37","author":"Parker","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0070","first-page":"14","article-title":"Nanoparticle delivery of novel PDE4B inhibitor for the treatment of alcoholic liver disease","author":"Ma","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0071","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0264278","article-title":"The impact of rifaximin on inflammation and metabolism in alcoholic hepatitis: a randomized clinical trial","volume":"17","author":"Kimer","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0072","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/liv.15207","article-title":"Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: a pilot study (RIFA-AH)","volume":"42","author":"Jimenez","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0073","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1001\/jama.2023.4902","article-title":"Effect of prophylactic antibiotics on mortality in severe alcohol-related hepatitis: a randomized clinical trial","volume":"329","author":"Louvet","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0074","doi-asserted-by":"crossref","first-page":"e00306","DOI":"10.14309\/ctg.0000000000000306","article-title":"No effect in alcoholic hepatitis of gut-selective, broad-spectrum antibiotics on bacterial translocation or hepatic and systemic inflammation","volume":"12","author":"Stoy","year":"2021","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0075","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S1665-2681(19)30863-4","article-title":"Treatment with metadoxine and its impact on early mortality in patients with severe alcoholic hepatitis","volume":"13","author":"Higuera-de la Tijera","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0076","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.3748\/wjg.v21.i16.4975","article-title":"Metadoxine improves the three- and six-month survival rates in patients with severe alcoholic hepatitis","volume":"21","author":"Higuera-de la Tijera","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0077","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1111\/liv.13430","article-title":"Interleukin-1 inhibition facilitates recovery from liver injury and promotes regeneration of hepatocytes in alcoholic hepatitis in mice","volume":"37","author":"Iracheta-Vellve","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0078","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","article-title":"An open-label, dose-escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcohol-associated hepatitis","volume":"72","author":"Arab","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0079","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/hep.22317","article-title":"Granulocyte-colony stimulating factor induces proliferation of hepatic progenitors in alcoholic steatohepatitis: a randomized trial","volume":"48","author":"Spahr","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0080","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/ajg.2014.154","article-title":"Granulocyte colony-stimulating factor in severe alcoholic hepatitis: a randomized pilot study","volume":"109","author":"Singh","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0081","first-page":"e10474","article-title":"Efficacy of granulocyte colony stimulating factor in severe alcoholic hepatitis: a systematic review and meta-analysis","volume":"12","author":"Baig","year":"2020","journal-title":"Cureus"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0082","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101689","article-title":"A phase II, multicenter, open-label, randomized trial of pegfilgrastim for patients with alcohol-associated hepatitis","volume":"54","author":"Tayek","year":"2022","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0083","first-page":"S150","article-title":"GCSF increases the steroid responsiveness and 90 day survival in severe alcoholic hepatitis patients\u2014a randomised control trial","volume":"76","author":"Mishra","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0084","doi-asserted-by":"crossref","first-page":"1852","DOI":"10.1056\/NEJM199106273242604","article-title":"Improvement by acetylcysteine of hemodynamics and oxygen transport in fulminant hepatic failure","volume":"324","author":"Harrison","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0085","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1053\/j.gastro.2015.06.006","article-title":"Comparative effectiveness of pharmacological interventions for severe alcoholic hepatitis: a systematic review and network meta-analysis","volume":"149","author":"Singh","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0086","article-title":"ACG Clinical Guideline: Alcohol-Associated Liver Disease","author":"Jophlin","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0087","first-page":"2279","article-title":"[Dietetics in alcoholic hepatitis; therapeutic role of cheese]","volume":"27","author":"Richet","year":"1951","journal-title":"Sem Hop"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0088","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.alcohol.2008.08.006","article-title":"Probiotics restore bowel flora and improve liver enzymes in human alcohol-induced liver injury: a pilot study","volume":"42","author":"Kirpich","year":"2008","journal-title":"Alcohol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0089","first-page":"10","article-title":"Beneficial shifts in gut microbiota by Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 in alcoholic hepatitis","author":"Gupta","year":"2022","journal-title":"Microorganisms"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0090","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.cgh.2016.10.029","article-title":"Healthy donor fecal microbiota transplantation in steroid-ineligible severe alcoholic hepatitis: a pilot study","volume":"15","author":"Philips","year":"2017","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0091","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-022-10438-0","article-title":"Fecal microbiota transplantation compared with prednisolone in severe alcoholic hepatitis patients: a randomized trial","volume":"17","author":"Pande","year":"2023","journal-title":"Hepatol Int"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0092","doi-asserted-by":"crossref","first-page":"2043","DOI":"10.1056\/NEJMoa1910437","article-title":"Drug-resistant E. coli bacteremia transmitted by fecal microbiota transplant","volume":"381","author":"DeFilipp","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0093","doi-asserted-by":"crossref","first-page":"S34","DOI":"10.1016\/S0168-8278(22)00480-9","article-title":"Il-1beta signal inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)","volume":"77","author":"Vergis","year":"2022","journal-title":"J Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0094","article-title":"Safety, pharmacokinetics, and efficacy signals of larsucosterol (DUR-928) in alcohol-associated hepatitis","author":"Hassanein","year":"2023","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0095","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jceh.2015.07.037","article-title":"Corticosteroids and bovine colostrum in treatment of alcoholic hepatitis \u2018in extremis\u2019: a pilot study","volume":"5","author":"Sidhu","year":"2015","journal-title":"J Clin Exp Hepatol"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0096","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1111\/j.1530-0277.1998.tb03915.x","article-title":"Hyperhyaluronanemia in alcoholic hepatitis is associated with increased levels of circulating soluble intercellular adhesion molecule-1","volume":"22","author":"Hill","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0097","first-page":"24","article-title":"Hyaluronic acid as a biomarker of fibrosis in chronic liver diseases of different etiologies","volume":"89","author":"Orasan","year":"2016","journal-title":"Clujul Medical"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0098","doi-asserted-by":"crossref","first-page":"451","DOI":"10.18388\/abp.2016_1443","article-title":"The role of serum hyaluronic acid determination in the diagnosis of liver fibrosis","volume":"64","author":"Gudowska","year":"2017","journal-title":"Acta Biochimica Polonica"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0099","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1002\/hep.29144","article-title":"MicroRNA 181b-3p and its target importin alpha5 regulate toll-like receptor 4 signaling in Kupffer cells and liver injury in mice in response to ethanol","volume":"66","author":"Saikia","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.clinthera.2023.10.013_bib0100","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s40472-022-00387-w","article-title":"Acute alcohol-associated hepatitis in the COVID-19 pandemic\u2014a structured review","volume":"9","author":"Schulz","year":"2022","journal-title":"Curr Transplant Rep"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291823004058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T09:00:01Z","timestamp":1758963601000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291823004058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":99,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S0149291823004058"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.10.013","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Past, Present, and Future Therapies for Alcohol-associated Hepatitis","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2023.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc.","name":"copyright","label":"Copyright"}]}}